{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T17:33:46Z","timestamp":1760549626123},"reference-count":45,"publisher":"American Society for Microbiology","issue":"1","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2015,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Mother-to-child transmission (MTCT) of HIV-1 remains a global health problem. The World Health Organization (WHO) recommendations advise the administration of a once-daily, oral, prophylactic regimen of the nonnucleoside reverse transcriptase inhibitor nevirapine (NVP) from birth until 4 to 6 weeks of age for infants born to HIV-infected mothers in regions without access to safe and nutritionally adequate alternatives to breast milk. A critical factor driving the successful implementation of the WHO guidelines involves sustaining high adherence to the frequent dosing. With these challenges in mind, we have developed the first injectable, sustained-release NVP formulations with the goal of providing, for 6 weeks or longer, preventative plasma drug levels from a single subcutaneous administration at birth. The long-acting NVP consists of large (&gt;50 \u03bcm), monodisperse NVP particles coated with biocompatible polymers that control the drug release kinetics. Two lead formulations exhibiting burst-free, sustained-release kinetics for up to 75 days\n            <jats:italic>in vitro<\/jats:italic>\n            were developed. Subsequent\n            <jats:italic>in vivo<\/jats:italic>\n            studies in rats demonstrated no toxicity related to the formulations. Rat plasma NVP concentrations were above the analytical assay's limit of quantification for up to 28 days. Pharmacokinetic analysis of the rat plasma NVP concentration-time data allowed absorption rate constants to be calculated. These data then were used to simulate infant NVP exposure from a single injected dose (&lt;200 mg) of our long-acting formulations, demonstrating preliminary feasibility of the technology to maintain safe, preventative NVP plasma levels (0.2 to 3.0 \u03bcg ml\n            <jats:sup>\u22121<\/jats:sup>\n            ) for 6 weeks or longer.\n          <\/jats:p>","DOI":"10.1128\/aac.03906-14","type":"journal-article","created":{"date-parts":[[2014,10,14]],"date-time":"2014-10-14T03:23:42Z","timestamp":1413257022000},"page":"59-66","update-policy":"http:\/\/dx.doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":18,"title":["Pharmacokinetics of Injectable, Long-Acting Nevirapine for HIV Prophylaxis in Breastfeeding Infants"],"prefix":"10.1128","volume":"59","author":[{"suffix":"Jr.","given":"John M.","family":"Cortez","sequence":"first","affiliation":[{"name":"Auritec Pharmaceuticals, Inc., Pasadena, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafaela","family":"Quintero","sequence":"additional","affiliation":[{"name":"Auritec Pharmaceuticals, Inc., Pasadena, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John A.","family":"Moss","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Oak Crest Institute of Science, Pasadena, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Beliveau","sequence":"additional","affiliation":[{"name":"Pharsight Consulting Services, Montreal, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas J.","family":"Smith","sequence":"additional","affiliation":[{"name":"Auritec Pharmaceuticals, Inc., Pasadena, California, USA"},{"name":"Department of Chemistry, Oak Crest Institute of Science, Pasadena, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc M.","family":"Baum","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Oak Crest Institute of Science, Pasadena, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","volume-title":"Global report: UNAIDS report on the global AIDS epidemic 2013","author":"Joint United Nations Programme on HIV\/AIDS","year":"2013","unstructured":"Joint United Nations Programme on HIV\/AIDS. 2013. Global report: UNAIDS report on the global AIDS epidemic 2013. Joint United Nations Programme on HIV\/AIDS, Geneva, Switzerland."},{"key":"e_1_3_3_3_2","volume-title":"Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: recommendations for a public health approach","author":"World Health Organization","year":"2010","unstructured":"World Health Organization. 2010. Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: recommendations for a public health approach. World Health Organization, Geneva, Switzerland."},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.9.1175"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)80008-7"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)14341-3"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.282.8.744"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.9.1167"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00314990"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-409X(02)00090-X"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.2174\/1568005033481079"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2009.15.9.728"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.18.3.193"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)16108-4"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)09742-8"},{"key":"e_1_3_3_16_2","first-page":"357","article-title":"Correlation of in vitro-in vivo release rates for sustained release nevirapine implants in rats","volume":"101","author":"Chen J","year":"2005","unstructured":"Chen J, Walters K, Ashton P. 2005. Correlation of in vitro-in vivo release rates for sustained release nevirapine implants in rats. J Control Release 101:357\u2013358.","journal-title":"J Control Release"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0020247"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1242\/jeb.01589"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2009.00267.x"},{"key":"e_1_3_3_20_2","volume-title":"Pharmacokinetic and pharmacodynamic data analysis: concepts and applications","author":"Gabrielsson J","year":"2006","unstructured":"Gabrielsson J, Weiner D. 2006. Pharmacokinetic and pharmacodynamic data analysis: concepts and applications, 4th ed. Swedish Pharmaceutical Press, Stockholm, Sweden.","edition":"4"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00741-11"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270012448397"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600760118"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11167-005-0470-1"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.3349\/ymj.2000.41.6.720"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000002"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.2217\/nnm.12.214"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm0414-323"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e328357f5ad"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00267-13"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1248707"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2014.118"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2011.09.041"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0928-0987(01)00095-1"},{"key":"e_1_3_3_35_2","volume-title":"Pharmaceutical dosage forms and drug delivery systems","author":"Ansel H","year":"1999","unstructured":"Ansel H, Allen LV, Popovich NG. 1999. Pharmaceutical dosage forms and drug delivery systems, 7th ed. Lippincott Williams & Wilkins, Philadelphia, PA.","edition":"7"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(02)02396-8"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200418020-00005"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270002250613"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2011.07.047"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm1777"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1097\/QCO.0b013e328332c54d"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.75.11.4999-5008.2001"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200312150-00006"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199903110-00006"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2006.22.232"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.3851\/IMP1803"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.03906-14","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.03906-14","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T22:57:39Z","timestamp":1645484259000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.03906-14"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["10.1128\/AAC.03906-14"],"URL":"https:\/\/doi.org\/10.1128\/aac.03906-14","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,1]]},"assertion":[{"value":"2014-07-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-10-03","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-12-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}